Sensex rises; Infosys jumps as CEO appointment brings peace hopes

Image
Reuters
Last Updated : Dec 04 2017 | 12:25 PM IST

By Jessica Kuruthukulangara

(Reuters) - Indian stocks rose on Monday as Infosys Ltd rallied on hopes that the appointment of a new CEO would help the company move on from a feud between its board and founders that had pummelled shares.

Sentiment was also lifted by stronger Asian shares after the passage of a tax bill by the U.S. Senate on Saturday, although worries that the bill would lead to liquidity tightening in emerging markets weighed on investors.

Any gains in Indian shares are also likely to be capped ahead of the Reserve Bank of India's policy meeting on Wednesday. Although the central bank is widely expected to keep rates on hold, investors will watch for any hints of a cut at the February meeting in its statement.

"We had a positive opening in line with Asian peers. We also had some index heavyweights supporting positivity, putting a temporary stop to the negativity that we had seen late last week," said Anand James, chief market strategist, Geojit Financial Services.

However, markets still look a little hesitant going into the last month of the year, he added.

The broader NSE Nifty was up 0.27 percent at 10,149.25 as of 0635 GMT, while the benchmark BSE Sensex was 0.32 percent higher at 32,938.69. Both indexes were headed for their first session of gain in five.

Infosys shares rose as much as 4 percent after the IT services company on Saturday named Salil Parekh as its new chief executive, handing him the twin challenges of reviving growth and forging peace between its founders and board following a public spat.

Infosys led gains on the Nifty IT index, which rose as much as 1.4 percent.

Among other top gainers on the NSE index, Tata Motors Ltd gained as much as 3.1 percent after posting a 58 percent jump in domestic commercial and passenger vehicles sales in November.

Biocon Ltd hit a record high after the drugmaker and its partner Mylan NV received U.S. FDA approval for generic cancer drug Ogivri.

(Reporting by Jessica Kuruthukulangara in Bengaluru; Editing by Subhranshu Sahu)

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Dec 04 2017 | 12:15 PM IST

Next Story